Bendamustine plus rituximab in Japanese patients with relapsed or refractory diffuse large B-cell lymphoma

This single-arm phase 3 study was conducted to confirm the results of our phase 2 study of bendamustine (B)-rituximab (R) in patients with relapsed/refractory diffuse large B cell lymphoma (rrDLBCL). The primary endpoint was overall response rate (ORR). Autologous stem cell transplantation-ineligible rrDLBCL patients with <= 2 prior chemotherapy regimens received R 375 mg/m(2) IV on day 1 and B 120 mg/m(2)/day IV on days 2 and 3 every 21 days up to 6 cycles. Thirty-eight patients with a median age of 74 years (range, 43-86) received BR. The ORR and complete response rates were 76.3% and 47.4%, respectively. With a median follow-up of 19.5 months including long-term follow-up, median progression-free survival was 11.9 months. Median OS was 29.2 months. Discontinuation of treatment due to Gr3-5 TEAE was observed among 13 of 38 patients (34.2%). One patient with cytomegalovirus enterocolitis died during follow-up. This BR regimen was confirmed to be effective and tolerable in studied patients. ClinicalTrials.gov Identifier: NCT03372837 registered on 14 December 2017, NCT04354402 registered on 21 April, 2020.

Automated summary

This study aimed to confirm the effectiveness and tolerability of bendamustine-rituximab combination therapy in patients with relapsed/refractory diffuse large B cell lymphoma. The results showed that the combination therapy was effective in achieving disease response and was well tolerated, with an overall response rate of 76.3% in the patients.